A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Clinical Cancer Research2021Vol. 27(17), pp. 4757–4767
Citations Over TimeTop 10% of 2021 papers
Sarah A. Weiss, Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia B. Jilaveanu, Amanda Ralabate, Barbara J. Johnson, Neta Shanwetter Levit, Gail D. Anderson, Daniel Zelterman, Wei Wei, Amit Mahajan, Ovid Trifan, Marcus Bosenberg, Susan M. Kaech, Curtis J. Perry, William Damsky, Scott Gettinger, Mario Sznol, Michael E. Hurwitz, Harriet M. Kluger
Abstract
This first in-human study of patients with anti-PD-1/PD-L1-resistant tumors treated with dual macrophage-polarizing therapy, with or without nivolumab demonstrated safety and pharmacodynamic activity. Optimization of the dosing frequency and sequence of this combination is warranted.
Related Papers
- → Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma(2018)4,536 cited
- → Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma(2021)4 cited
- → Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma(2022)4 cited
- → Should we use combination therapy for all advanced renal cell carcinoma?(2019)4 cited
- [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].(2019)